A Commentary on: Immunogenicity and Safety of a Recombinant COVID-19 Vaccine as Heterologous Booster After Priming with Inactivated Vaccine in Healthy Children and Adolescents Aged 3-17 Years: An Open-labeled, Single-arm Clinical Trial
Received Date: Jun 04, 2024 / Published Date: Jul 04, 2024
Abstract
World Health Organization and U.S. Centers for Disease Control and Prevention have issued guidance to encourage booster immunization due to declining antibody level of population who completed primary vaccination and the emergence of new variants. In this commentary, several important insights and findings from a clinical trial of a heterologous booster recombinant protein vaccine in children aged 3-17 years would be summarized: Booster immunization in minors could induce a satisfactory immune response; the level of neutralizing antibody induced by heterologous booster immunization was superior to that of homologous booster immunization. These findings would expand the application of booster immunization and provide reference for the formulation of relevant immunization strategies.
Keywords: COVID-19; Vaccine; Booster immunization; Minor
Citation: Hu Q, et al. (2024) A Commentary on: Immunogenicity and Safety of a Recombinant COVID-19 Vaccine as Heterologous Booster After Priming with Inactivated Vaccine in Healthy Children and Adolescents Aged 3-17 Years: An Open-labeled, Single-arm Clinical Trial. J Infect Dis Ther 12:597. Doi: 10.4172/2332-0877.1000597
Copyright: © 2024 Hu Q, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 343
- [From(publication date): 0-2024 - Dec 03, 2024]
- Breakdown by view type
- HTML page views: 308
- PDF downloads: 35
